Emtricitabine: all 177 studies that test it
Page 2 of 2. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedNCT04296695Phase 4
- Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIVTerminatedNCT04249037Phase 4
- Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV InfectionStatus unknownNCT04240509Phase 4
- A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate AgentsTerminatedNCT04236453Phase 1
- Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based RegimenStatus unknownNCT04155554Phase 3
- Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically SuppressedStatus unknownNCT04132674Phase 4
- Combination Antiretroviral Therapy (cART) for PBCCompletedNCT03954327Phase 2
- BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) StudyStatus unknownNCT03916328Phase 4
- Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)WithdrawnNCT03834909Phase 1
- Body Composition Sub-study of the D2EFT TrialCompletedNCT03675815Phase 4
- Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK StudyCompletedNCT03652623Phase 1/2
- Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1CompletedNCT03502005Phase 4
- The Kampala Women's Bone StudyCompletedNCT03464266Phase 4
- Same-Day Treatment With Genvoya vs. EFV/TDF/3TCWithdrawnNCT03405194Not applicable
- Western Australian Pre-exposure Prophylaxis for HIV Implementation TrialCompletedNCT03327155Phase 3
- Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and TenofovirCompletedNCT03309566Phase 4
- Reverse Transcriptase Inhibitors in Aicardi Goutières SyndromeWithdrawnNCT03304717Phase 1/2
- A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender WomenCompletedNCT03270969Phase 1
- Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological SuppressionCompletedNCT03251690Not applicable
- Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)TerminatedNCT03163277Phase 4
- The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender CommunityCompletedNCT03120936Phase 4
- Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part BStatus unknownNCT03120494Phase 4
- Prevention of HIV in "Île-de-France"Status unknownNCT03113123Not applicable
- Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral MedicationCompletedNCT03092206Phase 1
- Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender WomenCompletedNCT03060785Phase 1
- Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsCompletedNCT02984852Phase 1
- Expanded PrEP Implementation in Communities in NSWCompletedNCT02870790Phase 3
- Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune ActivationCompletedNCT02771054Phase 4
- Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionActive, not recruitingNCT02656511Phase 4
- HIV PrEP Priming of Immune EffectorsStatus unknownNCT02593409Phase 4
- Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.CompletedNCT02583464Phase 1
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedNCT02578550Phase 1
- A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male ParticipantsCompletedNCT02530060Phase 4
- Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedNCT02475135Phase 1
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnNCT02470650Phase 4
- Decrease of Neuropsychiatric Side Effects After Switching From Atripla to EvipleraTerminatedNCT02447016Phase 4
- Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive PatientsStatus unknownNCT02327715Phase 4
- Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B PatientsStatus unknownNCT02327702Phase 4
- Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis PatientsStatus unknownNCT02327689Phase 4
- Emtricitabine for Naive Child Chinese Chronic Hepatitis B PatientsStatus unknownNCT02327676Phase 4
- Emtricitabine for Naive Chinese Chronic Hepatitis B PatientsStatus unknownNCT02327663Phase 4
- Efavirenz to Dolutegravir Switch in Patients With CNS ToxicityStatus unknownNCT02285374Phase 4
- Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.CompletedNCT02198443Phase 4
- PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5CompletedNCT02149888Phase 4
- Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/TenofovirCompletedNCT02104700Phase 2/3
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingNCT02016924Phase 2/3
- Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited SettingCompletedNCT01772940Phase 4
- A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/RilpivirineCompletedNCT01701882Phase 3
- The Mochudi Prevention Project ART ProtocolTerminatedNCT01583439Not applicable
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)CompletedNCT01576731Phase 4
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)CompletedNCT01533272Phase 4
- Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy VolunteersCompletedNCT01276600Phase 1
- Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected PatientsCompletedNCT01274780Phase 4
- Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection StatusCompletedNCT01040091Phase 1
- Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
- Raltegravir Activity In Lymphoid TissuesWithdrawnNCT00863668Not applicable
- Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid MetabolismStatus unknownNCT00759070Phase 4
- An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric SubjectsCompletedNCT00642291Phase 2
- Comparison of Epzicom and Truvada for the Initial Once Daily HIV TreatmentCompletedNCT00544128Phase 4
- Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/MclCompletedNCT00532168Phase 4
- Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaCompletedNCT00528060Phase 2
- Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infectionCompletedNCT00476463Phase 2
- Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With TuberculosisStatus unknownNCT00474435Phase 2
- Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected PatientsCompletedNCT00365612Phase 4
- Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)CompletedNCT00334256Phase 2
- A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL StudyCompletedNCT00192634Phase 4
- Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)CompletedNCT00158457Phase 3
- The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral RegimensCompletedNCT00152061Not applicable
- Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-InfectionCompletedNCT00127959Phase 4
- Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)CompletedNCT00115609Phase 3
- Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 PatientsCompletedNCT00106379Phase 4
- Three Month Course of Anti-HIV Medications for People Recently Infected With HIVWithdrawnNCT00087464Not applicable
- Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve SubjectsCompletedNCT00043966Phase 3
- Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIVStatus unknownNCT00017992Phase 2
- A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV DrugsStatus unknownNCT00006208Phase 3
- A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsSuspendedNCT00002362Phase 3
- The Safety and Effectiveness of 524W91CompletedNCT00002335Phase 1